At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,181 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Atrial Fibrillation Patients Defined as Population With a Low Risk of Stroke Based on a CHA2DS2-VASc Score
In Brief
An observational study for Atrial Fibrillation. Completed, enrolled 1,181 participants across 9 sites.
Detailed Summary
The purposes of this study are to assess the prevalence of patients with a low risk of stroke or systemic embolism based on a CHA2DS2-VASc score among patients who have an AF-related thromboembolism and to identify the clinical and laboratory risk factors associated with thromboembolism in AF patients with a CHA2DS2-VA score of 0 or 1.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesSouth Korea
CollaboratorsSamjin Pharmaceutical Co., Ltd.
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartApr 2017
First PostedMay 2017
Primary CompletionFeb 2018
Study CompletionJun 2018
TodayJul 2026
First PostedMay 10, 2017
Enrollment StartApr 6, 2017
Primary CompletionFeb 20, 2018
Study CompletionJun 14, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.1 years ago